Ignite Creation Date:
2024-05-05 @ 11:18 PM
Last Modification Date:
2024-10-26 @ 10:31 AM
Study NCT ID:
NCT01291420
Status:
COMPLETED
Last Update Posted:
2023-05-12
First Post:
2011-02-07
Brief Title:
Dendritic Cell Vaccination for Patients With Solid Tumors
Sponsor:
University Hospital Antwerp
Organization:
University Hospital Antwerp
Study Overview
Official Title:
Therapeutic Efficacy of Wilms Tumor Gene WT1 mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors a Phase IFeasibility Study
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells DCs - engineered to express the WT1 protein - in patients with limited spread metastatic solid tumors ie breast cancers glioblastoma grade IV sarcomas malignant mesothelioma and colorectal tumors Based on the results of our previously performed phase I study with autologous WT1 mRNA-transfected DC the investigators hypothesize that the vaccination with DC will be well-tolerated and will result in an increase in WT1-specific CD8 T cell responses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None